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http://dx.doi.org/10Intratumor heterogeneity can confound the results of mutation analyses in oncodriver genes us-
ing traditional methods thereby challenging the application of targeted cancer therapy strategies
for patients Ultradeep sequencing can detect low frequency and expanded clonal mutations in
primary tumors to better inform treatment decisions. KRAS coding exons in 61 treatment-naive
colorectal cancer (CRC) tumors and KRAS, EGFR, ALK, and MET in lung tumors from three Chi-
nese non-small cell lung cancer (NSCLC) patients were sequenced using ultradeep sequencing
methods. Forty-one percent of CRC patients (25/61) harbored mutations in the KRAS active
domain, eight of which (13%) were not detected by Sanger sequencing. Three (of eight) had fre-
quencies less than 10% and one patient harbored more than one mutation. Low frequency KRAS
active (G12R) and EGFR kinase domain mutations (G719A) were identified in one NSCLC
patient. A second NSCLC patient showed an EML4-ALK fusion with ALK, EGFR, and MET mu-
tations. A third NSCLC patient harbored multiple low frequency mutations in KRAS, EGFR, and
MET as well as ALK gene copy number increases. Within the same patient, multiple low fre-
quency mutations occurred within a gene. A complex pattern of intrinsic low frequency driver
mutations in well-known tumor oncogenes may exist prior to treatment, resulting in resistance
to targeted therapies. Ultradeep sequencing can characterize intratumor heterogeneity and iden-
tify such mutations to ultimately affect treatment decisions.
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Open access One of the major paradigm shifts over the past 15 years in
anticancer therapy is the introduction of targeted therapy.
This approach differs from nonspecific first-line treatments
by focusing on activated protein targets related to cellular
growth and proliferation and antiapoptotic processes. Such
treatment strategies have proven to be highly effective,
specifically when applied to aggressive cancers in certain
patients, although, typically, clinical improvement is not
sustained. Recent findings show that low frequency
variants within the genes that code for these targets mayunder CC BY-NC-ND license.
Oncogenic driver genes in CRC and NSCLC 331potentially explain this lack of sustained benefit in patients
(1).
Epidermal growth factor receptor (EGFR) is one important
target for cancer therapy. Monoclonal antibodies (mAb) such
as cetuximab (Erbitux) (Bristol-Myers Squibb, New York City,
NY and Eli Lilly, Indianapolis, IN) and panitumumab (Vectibix)
(Amgen, Thousand Oaks, CA), which are directed against
EGFR, have proven to be effective in the treatment of meta-
static colorectal cancer (mCRC). In addition, EGFR tyrosine
kinase inhibitors (TKIs) such as gefitinib (IRESS) (AstraZe-
neca, London, UK) and erlotinib (Tarceva) (Genentech, San
Francisco, CA) have shown clinical efficacy by inhibiting the
activating mutations in EGFR in patients with non-small cell
lung cancer (NSCLC). More recently, the presence of a fusion
gene, echinoderm microtubule-associated protein-like 4-
anaplastic lymphoma kinase (EML4-ALK ), has been identi-
fied as the driver mutation in a subgroup of NSCLC patients
(2). The clinical features of lung cancer patients that harbor
EML4-ALK include light- or never-smokers, younger age, the
presence of adenocarcinomas with acinar pattern or signet
ring adenocarcinoma, and a lack of EGFR or Kirsten rat sar-
coma viral oncogene homologue (KRAS ) gene mutations (3).
Subsequent studies have led to the approval of crizotinib
(XALKORI) (Pfizer, New York, NY) therapy in patients
harboring this variant (4). The average frequency of this gene
fusion across different ethnic populations is reported to be
approximately 3.4% in unselected NSCLC patients and 4.5%
in adenocarcinoma-enriched NSCLC patients (5), with a
higher frequency in the Chinese population in both unselected
NSCLC patients (4.9e11.7%) and in adenocarcinoma-
enriched NSCLC patients (5.3e16.1%) (6,7).
KRAS is an important driver in the rat sarcoma/mitogen-
activated protein kinase (RAS/MAPK) pathway that links
EGFR activation to cell proliferation and survival. The asso-
ciations among certain KRAS mutations and the effective-
ness of anti-EGFR treatments in patients with CRC have
been reported in numerous studies (8e12). Mutations
affecting KRAS G12 or G13 residues cause over-activation
of the RAS/MAPK pathway, and as signal transduction is
activated at the level of KRAS proteins, upstream inhibition
by EGFR-targeted agents becomes ineffective. Epidemio-
logic studies suggest that KRAS mutations may be a nega-
tive predictive biomarker for treatment with EGFR-TKIs in
NSCLC as well as CRC (13), though due to the mutually
exclusive relationship between KRAS and EGFR mutations
in NSCLC and CRC, it is generally believed that KRAS mu-
tations will have minimal impact on the effectiveness of
EGFR-TKI treatment in NSCLC patients (13).
Currently, physicians depend on traditional mutation-
detection strategies to guide treatment decisions with tar-
geted therapiesdthe gold standard for assays being Sanger
sequencing, allele-specific polymerase chain reactions (PCRs)
(e.g., amplification refractory mutation system [ARMS]-PCR),
or fluorescence in situ hybridization (FISH). For example,
KRAS mutation status is required in all mCRC patients who
may receive anti-EGFR mAb therapy, and the detection of the
activating mutations within the EGFR gene in NSCLC patients
is a routine diagnostic determinant for gefitinib or erlotinib
treatment. Additionally, the Vysis ALK Break Apart FISH Probe
Kit (Abbott Molecular, Des Plaines, IL), which detects rear-
rangements of the ALK gene, was approved as a companion
diagnostic test for crizotinib treatment. However, even withinpatient subgroups harboring such variants, not all respond to
the targeted treatment. The first-line treatment response rates
of EGFR-TKIs in patients with NSCLC containing EGFR mu-
tations are 55e90% (14), and the responding patients even-
tually develop resistance to the targeted therapy. Either
secondary mutations of EGFR or the amplification of c-MET
(hepatocyte growth factor receptor) are responsible for only
50% of these EGFR-TKI resistance cases, leaving unknown
molecular attribution for roughly half of the remaining patient
population. Other biomarkers, such as phosphatidylinositol-
4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA)
mutations, and loss of phosphatase and tensin homologue
(PTEN ), have been investigated, and their impacts on clinical
efficacies of anti-EGFR therapies are not conclusive (8,15).
Traditional mutation-detection strategies reveal only mu-
tations occurring in most cancer cells, namely, the expanded
clonal population, while neglecting low frequency sub-
stitutions. Further, the technical limitations of detection
sensitivity in traditional sequencing procedures have typically
prevented the detection of these low frequency mutations. In
principle, next-generation sequencing (NGS) technologies
can provide a valid solution, as they rely on amplification and
sequencing of distinct DNAmolecules, and since sensitivity of
NGS increases with depth and coverage, rare mutations are
more readily detectablewith ultradeep resequencing of a given
DNA region. The detection of these low frequency mutations,
in addition to expanded clonal mutations, is critical to under-
standing the mechanisms that resist cancer targeted therapy.
To further explore the presence and potential impact that
low frequency somatic mutations in oncodriver genes may
have in the resistance to targeted therapies, we sequenced
the coding exons of KRAS in 61 treatment-naive CRC pa-
tients using targeted ultradeep resequencing. With the
extraordinary depth used here, we found that three patients
(5%) harbored low frequency mutations (variant frequencies
[Vfs] <10%) and eight patients had Vfs less than 27% in
guanosine triphosphate (GTP)ease nucleotide biding sites
that were not detected using Sanger sequencing. We also
sequenced the coding exons of EGFR, KRAS, ALK, and
MET in tumor biopsies from three Chinese NSCLC patients.
We found the coexistence of a low frequency KRAS active
mutation (G12R) and EGFR kinase domain mutation
(G719A) in tumor specimens in one NSCLC patient, an
EML4-ALK fusion with ALK, EGFR, and MET mutations in
the second patient, and multiple coexisting low frequency
mutations in KRAS, EGFR, and MET with an ALK gene copy
number increase in the third patient. We also found that
multiple low frequency mutations were present in a single
gene from the same CRC or NSCLC patients. These data
suggest that intrinsic low frequency driver mutations, some-
times on different oncodrivers, in cancer tissues may exist
prior to treatment, providing direct evidence for the cause of
unsustainable clinical improvement in cancer patients un-
dergoing monospecific targeted therapies.
Materials and methods
CRC and NSCLC sample summary
Sixty-one fresh frozen colon rectum tumors and six normal
colon specimens were purchased from ILSbio (Chestertown,
332 L. Jiang et al.MD) and Asterand (Detroit, MI). All tumors were from
treatment-naive patients diagnosed with stage I to IIIC
adenocarcinoma of the colon or rectum. Tumor specimens
were from white patients, with 28 females and 33 males and
an age range of 32e84 years. Normal tissue specimens were
from Vietnamese males with ages ranging from 10 to 42
years. Of the 61 CRC patients, the coding regions of KRAS
were sequenced at least twice, inclusive of independent li-
brary preparations and sequencing runs in 21 patients (eight
patients sequenced at least three times) on the Illumina
HiSeq sequencing platform (San Diego, CA). In addition,
samples from a subset of 15 CRC patients from the set of
61 who harbored variants in both pathogenic (i.e., residues
10e17) and nonpathogenic loci of KRAS (Vf range
1.01e51.12%) were sequenced again using a completely
independent sequencing platform, Ion Personal Genome
Machine (PGM) (Life Technologies, Carlsbad, CA), to verify
variant calls made initially using the Illumina HiSeq platform.
The NSCLC specimens were collected from three
treatment-naive patients from Shanghai Chest Hospital. For
patients A and C, two independent biological specimens
were procured, and each was replicated in two independent
library preparations and sequencing runs. For patient B,
there was only a single biological specimen procured, and
this was not replicated by sequencing. The study protocol
and all NSCLC specimens were approved by the ethics
committee at Shanghai Chest Hospital.
DNA extraction, library preparation, and
sequencing
DNA extractions from fresh frozen tissue were performed
using the Qiagen DNeasy Blood and Tissue Kit (German-
town, MD) following the manufacturer’s suggested protocol.
DNA extractions from formalin-fixed paraffin-embedded
(FFPE) tissue were performed using the Ambion RecoverAll
Total Nucleic Acid Isolation Kit (Life Technologies) following
the manufacturer’s instructions.
Target sequencing libraries for Illumina HiSeq sequencing
were prepared using the Fluidigm Access Array System (San
Francisco, CA) using multiplexed sample barcoding and
amplicon tagging following the manufacturer’s instruction.
Targeted libraries were prepared for Ion PGM sequencing
using Life Technologies’ AmpliSeq protocol for the KRAS
gene.
The Illumina sequencing libraries were normalized and
run on the Illumina HiSeq 2000 Instrument using a 100ebase
pair paired-end sequencing read protocol. Targeted libraries
were also prepared by AmpliSeq with the same DNA sam-
ples using the Ion OneTouch 2 System (Life Technologies)
and were sequenced on the Ion PGM 318 Chip (Life
Technologies).
Dilution series to determine limit of detection
A selection of four CRC tumor DNA samples (from the cohort
of 61 patients) harboring known cancer-specific mutations in
KRAS at pathogenic loci (protein codons 12 and 13; DNA:
chr12: 25398284 and chr12: 25398281, respectively,
GRCh37/hg19) and four normal healthy colon specimens
were diluted serially in a normal human whole blood genomicDNA sample background in a 1:2 fashion for seven iterations
to establish a titration from the original Vf. This titration
method brought the expected Vf to below 1% for each of the
samples. Each of the stock and diluted samples were then
prepared using the specific amplicons in KRAS, mothers
against decapentaplegic homologue 4 (SMAD4), tumor pro-
tein p53 (TP53), mutL homologue 1 (MLH1), kinase insert
domain receptor (KDR), fibroblast growth factor receptor 1
(FGFR1), and v-kit Hardy-Zuckerman 4 feline sarcoma viral
oncogene homologue (KIT ) in the TruSeq Amplicon Cancer
Panel (Illumina) following the manufacturer’s protocol.
Samples were sequenced on the Illumina MiSeq instrument
with 150ebase pair paired-end sequencing. Vfs were
detected and the expected KRAS Vfs were calculated from
the dilution series to establish limits of detection for the
sequencing by synthesis chemistry.
FISH
The EML4-ALK fusion was detected by FISH assays on 4-
micron FFPE sections. FISH probes were generated inter-
nally by directly labeling bacterial artificial chromosome (BAC)
RP11-100C1 (Life Technologies) DNA with Spectrum Red
(cat no. 02N34-050) (Enzo Life Sciences, Farmingdale, NY)
for the ALK gene and BAC RP11-142M12 (Life Technologies)
with Spectrum Green (cat no. 02N32-050) (Enzo Life Sci-
ences) for the EML4 gene using a nick translation kit (cat no.
07J00-001) (Abbott Molecular) based on methods according
to the manufacturer’s instructions. Tissue MicroArray (TMA)
sections were deparaffinized and pretreated using the Spot-
Light Tissue Kit (cat no.00-8401) (Life Technologies) accord-
ing to the manufacturer’s instructions. Tissue sections and
ALK/EML4 probes were then codenaturated at 80C for 5
minutes and hybridized at 37C for 48 hours. Excess probe
was removed with posthybridization wash buffer (0.3% NP40/
1 saline-sodium citrate [SSC]) by washing the slides at 75C
for 5 minutes, followed by a wash with 2SSC at room tem-
perature for 2 minutes. Sections were then counterstained
with 0.3 mg/mL 40,6-diamidino-2-phenylindole (DAPI, H-1200)
(Vector Laboratories, Burlingame, CA), cover-slipped, and
stored at 4C until signal observation.
ALK and EML4 signals were observed under a fluores-
cence microscope (BX61) (Olympus, Tokyo, Japan) using a
100 objective and proper filters. Co-localization of red ALK
signal and green EML4 signal was defined as EML4-ALK
fusion positive. ALK gene copy number increase was defined
as an average copy number greater than four.
Sanger sequencing for KRAS exon 2
Sanger sequencing of KRAS exon 2 was performed to
assess codon 12 and 13 mutations in 61 CRC samples and 2
cell line controls (Calu-1 and HCT116). Thirty nanograms of
genomic DNA from each sample was amplified in duplicate
20 mL reactions containing 0.5 mmol/L forward and reverse
primers (Life Technologies) and 10 mL HotStar Taq Plus 2
Master Mix (Qiagen). The PCR program was as follows:
initial denaturation at 95C (5 min); 35 amplification cycles of
94C (30 s), 59C (30 s), 72C (1 min); and a final extension
at 72C (10 min). Amplification products were purified using
the QIAquick PCR purification kit (Qiagen) and eluted in
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Sequencing reactions were performed using 2 mL template
with 0.3 mmol/L forward or reverse primer and 2 mL BigDye
Terminator v3.1 Ready Reaction Mix in a 10 mL reaction (Life
Technologies). The sequencing program was as follows: 25
cycles of 96C (10 s), 50C (5 s), 60C (4 min). Extension
products were purified using the BigDye XTerminator purifi-
cation protocol and run on an Applied Biosystems 3730 DNA
Analyzer (Life Technologies). All samples were sequenced in
the forward and reverse directions (forward primer, 50
CGATACACGTCTGCAGTCAAC 30; reverse primer, 50
CCTGACATACTCCCAAGGAAAG 30).Data analysis
Following demultiplexing, FASTQ files generated from either
the Illumina HiSeq or MiSeq sequencing runs were aligned to
the human genome (UCSC hg19; Feb 2009 release;
Genome Reference Consortium GRCh37) using Bowtie2
(version 2.0.0-beta7) (16). For Ion Torrent sequencing runs,
the aligned Binary Alignment/Map (BAM) files from the
Torrent Mapping Alignment Program (TMAP) were used in
the downstream analysis pipeline. SAMtools (version 0.1.18)
was utilized to convert the aligned sequence data from
a Sequence Alignment/Map (SAM) to BAM format. The
data was subsequently sorted and indexed with SAMtools
software. The SAMtools mpileup function was used to sum-
marize base calls at each locus. Single nucleotide poly-
morphism (SNP) and insertion and deletion (INDEL) calls
were made with VarScan2 (version 2.3.2). SNPs and
INDELs were characterized as being significantly different
from the reference sequence if the variant to reference base
frequency was greater than 1%, the calculated VarScan2 P
value for variant calls (based on the Fisher exact test) was
less than 0.001, total minimum depth was greater than 500,
the variant minimum depth was greater than 5, and the base
quality value was greater than 30. All identified variants
within a particular sample were exported as a variant call
format (VCF) (version 4.1) file. VCFs were examined with
snpEff (version 3.0) for variant annotation and prediction of
variant effects on genes. Further data analyses, including
change-point regression for the titration experiment
(segmented R library) and graphs, were all created in R
(version 2.15.1) and Prism (version 5.10) (GraphPad Soft-
ware, La Jolla, CA).Results
Variant call limit of detection: titration experiment
To determine the level of detection for identifying rare so-
matic mutations with targeted ultradeep sequencing, two
different experiments were performed. The first was a dilu-
tion experiment designed to establish (i) where the break in
linearity occurred between Vfs and a titrated concentration of
tumor and (ii) the limit of detection for variant calling against a
negative control background. Colon tissue specimens from
four normal healthy donors were used as negative controls
and four different CRC patient specimens were selected that
harbored cancer specific mutations with high Vfs (>30%).These loci within the first nucleotide-binding domain were
used, since variants in this region are well characterized as
cancer hot spots with a large dynamic range of Vfs, while
they also provide an adequate number of data points at the
low Vf values after conducting serial dilutions. For each
dilution factor within each specimen (four CRC and four
healthy controls), healthy donor DNA from whole blood was
added at 1:2 serial dilutions, providing a range of 0.0078e1
dilution factors. Then the loci for each specimen were
sequenced using the Illumina MiSeq protocol. All samples
had depth greater than 3,000 , and variants were called as
described in the Materials and methods section.
The results for this experiment are provided in Figure 1A
and Supplementary Figures S1 and S2. The difference be-
tween the upper range of Vfs in the normal specimens and
closest CRC dilution data point occurs at a Vf of 1%. Addi-
tionally, change-point analysis calculated in a regression
between the relative error ([VfobservedVfexpected]/Vfexpected)
and variant index for each patient specimen indicates that
the break in linearity of the titration curve occurs at a Vf
greater than 1% (data not shown).
To show that this Vf threshold was not specific only to
KRAS, regions of six well-characterized cancer-associated
genes (SMAD4, TP53, MLH1, KDR, FGFR1, and KIT ) were
sequenced in the four CRC tumor patient specimens and
four normal colon tissue specimens using the same dilution
factors as for KRAS, and the Vfs of germline SNPs were
calculated. The germline SNPs served as variants with high
Vfs, akin to the pathogenic loci in KRAS used in the titration
study described previously. If the CRC or normal subject
specimen harbored the minor allele of the germline SNP
within the gene, there was a clear linear association be-
tween the Vf and the dilution factor. If the CRC or normal
subject did not harbor the minor allele of the germline SNP
(i.e., it was homozygous to reference), the mean Vf plus
one standard deviation (SD) of the Vfs were below a Vf
threshold of 1% at all dilution levels and all genes, with the
exception of the first dilution level in KDR, which was
slightly higher than 1% but less than 2% (Supplementary
Figure S3). This study demonstrates that the Vf threshold
identified is not specific to KRAS and can be applied to
other genes.Variant call limit of detection: reproducibility
experiment
The second experiment was based on replication of variants
identified using two independent sequencing proto-
colsdIllumina HiSeq and Ion PGM. This strategy was
developed to show what variant calls exceed sequencing
error rates (Illumina sequencing instruments range from 0.05
to 1%) and show reproducibility using an independent
sequencing technology (17e20). We selected 15 CRC pa-
tient specimens with Vfs ranging from 1.01 to 51.12% from
the Illumina HiSeq protocol to be rerun on the Ion PGM
platform, from the pool of 61. The same variant caller as
described in the Materials and methods section was used for
both protocols. Of the 15 CRC patients, all KRAS coding
variants identified with Vfs greater than 2% from the Illumina
HiSeq protocol reproduced using the Ion PGM protocol (eight
variants within seven patients). Figure 1B demonstrates the
Figure 1 (A) Observed Vfs for four normal healthy control participants (mean  1SD) and four CRC participants for two KRAS
pathogenic loci (codons 13 and 12; DNA 25,398,281 and 25,398,284, GRCh37/hg19) across an eight-level 1:2 serial dilution series.
The x- and y-axes have been transformed with a square root to better illustrate the lower Vf detection limit. The dashed line indicates a
VfZ 1%, and lines for the four CRC participants are calculated using a least squares fit. (B) Reproducibility of variant frequencies (Vfs
 2%) for six CRC participants on two independent detection platforms at KRAS DNA locus 25,398,284; HiSeq (blue bars) and Ion
PGM (red bars). For a combined plot of CRC participant specimens for both loci in (A) on the original Vf scale, see Supplemental
Figures 1 and 2.
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called in codon 12 (six patients). Those variants originally
identified using the Illumina HiSeq protocol with Vfs ranging
from 1.01 to 1.89% did not reproduce using the Ion PGM
protocol. Though there are inherent differences in
sequencing sensitivity for both platforms, those variants
called with Vfs greater than 2% on the Illumina HiSeq
reproduced on the Ion PGM platform. This result, in combi-
nation with the dilution experiment, supports a conservative
threshold of 2% or greater for a true positive variant call,
which was implemented for all subsequent analyses reported
in this study.Error rates at variant calling threshold
We next evaluated the error rates at a 2% or greater Vf
threshold for variant calling. The false-positive rate is iden-
tified by summating the number of variants called at the Vf
threshold within a negative control sample, or a sample that
would not be expected to harbor variants. Six normal healthy
donor colon specimens (two in addition to the four used in the
titration experiment) were used for this determination, as
beyond de novo mutations, normal colon tissue from healthy
donors would not be expected to contain somatic variants.
The most prevalent nucleotide alternative to the reference
Oncogenic driver genes in CRC and NSCLC 335genome was called across all coding loci of the KRAS gene
for each normal sample. All germline SNP loci were then
removed, and any locus with a Vf of 2% or greater in any of
the six normal samples was retained, which provided a
0.75% false-positive rate.
The false-negative rate can be assessed using positive
control samples (i.e., samples expected to harbor certain
variants), where the expected variants that fail to be called at
the defined Vf threshold are counted. In contrast to the false-
positive rate, the false-negative rate identification requires
ground truth determination for the presence of a variant that
is not being detected at the Vf threshold by deep sequencing.
In this study, we leveraged both the titration experiment and
an independent sequencing platform to identify these rates.
The titration experiment indicated a Vf threshold of more
than 1%, where there was an apparent difference between
tumor and normal Vfs at two well characterized oncogenic
hotspot loci, although only those variants with Vfs of 2% or
greater were independently validated using an alternative
sequencing technology. Thus any variant that failed to be
called at a Vf less than 2% was not reproduced in this study.
These results suggest that with a conservative Vf threshold
of 2% or greater, the likelihood of not calling a true variant is
very low. Additionally, if Sanger sequencing variant calls
were used as ground truths (i.e., true positives), then variants
with a Vf of less than 27% were all identified with deep
sequencing, providing a 100% true-positive rate.
Low frequency KRAS mutation was observed in
tumors from treatment-naive CRC patients
A total of 39 (63%) CRC patients harbored five unique non-
synonymous coding mutations, with 25 patients (41%) carrying
the known active mutations in the first nucleotide-binding
domain (residues 10e17) (Table 1). Eight CRC patients
(13%) harbored mutations in the GTPase nucleotide-binding
sites of KRAS that were not detected using Sanger
sequencing, and three of eight had Vfs less than 10%, with one
patient harboring more than one mutation (the distance be-
tween these twomutations prohibited determining a cis or trans
association). This information is illustrated in Figure 2.
Coexistence of low frequency active KRAS and
EGFR kinase domain mutations in a treatment-
naive Chinese NSCLC patient
The coding exons within KRAS and EGFR were sequenced
in a tumor biopsy from a treatment-naive Chinese NSCLC
patient (patient A). After we excluded germline poly-
morphisms, four nonsynonymous single nucleotide changes
were identified in EGFR (Supplemental Table 1). One of
these mutations was located in the extracellular domain, one
in the kinase domain, and two in the C-terminal cytoplasmic
domain. The kinase domain mutation is a well-characterized
active mutation of EGFR (G719A), which has been associ-
ated with sensitivity to EGFR-TKI drugs such as gefitinib and
erlotinib in NSCLC patients. Three (of four) of these muta-
tions were predicted to impact protein function, from the SIFT
database (21) and the Vfs ranged from 3.23 to 4.34%, with
the exception of that of the active mutation, which was
9.89%. EGFR variants in codons 1016 and 1034 weredetermined to be in trans. For this same NSCLC patient, we
also observed a single G12R mutation in KRAS with a low Vf
of 2.28%. The entire coding exons of ALK and MET were
also sequenced, revealing one novel nonsynonymous mu-
tation in the cytoplasmic domain of ALK with a Vf of 4.41%,
while one mutation in the cytoplasmic domain of the MET
gene was detected (Vf Z 2.07%) (Figure 3).
Coexistence of EML4-ALK fusion or ALK copy
number increase and EGFR, MET, and KRAS
mutations in tumor tissue from two treatment-
naive Chinese NSCLC patients
Two treatment-naive Chinese NSCLC patients were tested
for an EML4-ALK fusion using FISH analyses. Patient B was
positive for the EML4-ALK fusion (Figure 4A), and patient C
was identified with an ALK gene copy number increase, with
an average copy number of approximately 5 (Figure 4B).
To evaluate the mutations related to crizotinib resistance,
all coding exons of KRAS, EGFR, ALK, and MET were
sequenced in the tumors from these two NSCLC patients. The
summary of the mutation status for patient B is summarized in
Supplemental Table 2. Four novel nonsynonymous mutations
in ALK were identified in this patient; each of them was located
in the extracellular domain of this gene. One of these muta-
tions, L170P, was predicted to have damaging effects on
protein function, according to the SIFT database.
Eight novel nonsynonymous mutations were identified in
EGFR in this patient, with three of them predicted to have
damaging effects on protein function, according to the SIFT
database. Among these eight, the homozygous stop code
mutation E66* was located in the N-terminus of EGFR and
the homozygous deleterious mutation R832C was found in
the kinase domain of EGFR. One novel heterozygous mu-
tation was also identified in the extracellular domain of MET.
The Vfs of the mutations identified in patient B ranged from
10.35 to 99.85%. Variants in close proximity were assessed
for cis or trans relationships, or occurrence of shared variants
within the same clone. It was determined that the variants in
codons 170 and 173 in EGFR were in cis, while the variants
in codons 173 and 182 were in trans.
The summary of the mutation status for patient C is pro-
vided in Supplemental Table 3. One nonsynonymous muta-
tion was identified in ALK that was predicted to have
damaging effects on protein function (SIFT database). This
variant at codon 170 and the other variant in this gene at
codon 198 were determined to be in trans. Two non-
synonymous mutations were detected in EGFR. Among
them, one is located in the extracellular domain and is pre-
dicted to have damaging effects on protein function (SIFT
database), while the other is in a serine-rich domain and
predicted to have damaging effects on protein function. One
nonsynonymous mutation was found in the C-terminal region
of KRAS, R164*, which is a stop codon mutation and results
in a truncated KRAS protein. One nonsynonymous mutation
was found in MET, located in the extracellular domain. The
Vfs of the five nonsynonymous mutations in patient C ranged
from 2.08 to 3.84%. Although four of these mutations each
had an entry in the Single Nucleotide Polymorphism data-
base (dbSNP), we classified these SNPs as cancer-specific
mutations with the following considerations: (i) the Vfs of
Table 1 Summary of mutations identified within the first nucleotide-binding domain (residues 10e17) in KRAS in tumor specimens from 25 CRC patients
Patient Chr Physical position Genotype Codon
Amino acid
change Sanger result Ref Reads Var reads
Variant
frequency (%) dbSNP ID
Confirmed by
Ion PGM
1 12 25398284 C/T 12 G/D G/D 249584 176771 41.45 rs121913529 Not examined
2 12 25398281 C/T 13 G/D G/D 294912 137593 31.72 rs112445441 Not examined
6 12 25398284 C/A 12 G/V G/V 167032 146537 46.62 rs121913529 Yes
8 12 25398284 C/A 12 G/V Negative 323608 107178 24.85 rs121913529 Not examined
10 12 25398279 C/T 14 V/I Negative 466547 43473 8.52 rs104894365 Yes
13 12 25398284 C/T 12 G/D G/D 225479 265428 54.05 rs121913529 Not examined
14 12 25398281 C/T 13 G/D G/D 303499 154506 33.72 rs112445441 Not examined
16 12 25398284 C/T 12 G/D G/D 280184 112988 28.73 rs121913529 Not examined
17 12 25398284 C/T 12 G/D G/D 268793 210304 43.88 rs121913529 Yes
18 12 25398285 C/T 12 G/S G/S 185069 82814 30.89 rs121913530 Not examined
19 12 25398284 C/T 12 G/D Negative 330901 10386 3.04 rs121913529 Yes
20 12 25398284 C/T 12 G/D G/D 387693 139363 26.44 rs121913529 Not examined
21 12 25398284 C/A 12 G/V G/V 142621 317999 68.79 rs121913529 Not examined
22 12 25398284 C/A 12 G/V Negative 286307 89578 23.79 rs121913529 Not examined
23 12 25398284 C/T 12 G/D G/D 267279 116448 30.33 rs121913529 Yes
24 12 25398284 C/T 12 G/D Negative 381445 10224 2.61 rs121913529 Yes
25 12 25398284 C/T 12 G/D G/D 269119 214402 44.33 rs121913529 Not examined
30 12 25398284 C/A 12 G/V G/V 312311 232101 42.51 rs121913529 Not examined
31 12 25398285 C/A 12 G/C G/C 187782 234737 55.06 rs121913530 Not examined
32 12 25398284 C/A 12 G/V G/V 283896 141116 33.13 rs121913529 Not examined
33 12 25398284 C/A 12 G/V Negative 412155 64179 13.45 rs121913529 Not examined
35 12 25398281 C/T 13 G/D G/D 168767 344810 67.09 rs112445441 Not examined
36 12 25398284 C/A 12 G/V Negative 276673 100422 26.56 rs121913529 Not examined
37 12 25398284 C/A 12 G/V Negative 378849 76508 16.78 rs121913529 Not examined
38 12 25398284 C/T 12 G/D G/D 180748 189179 51.12 rs121913529 Yes
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Figure 2 The distribution of mutations detected in 25 CRC
patients across the coding region codons of the KRAS gene.
Each point corresponds to a patient and each black tick mark in
the orange protein coding block indicates the presence of at
least one mutation identified in at least a single patient.
Oncogenic driver genes in CRC and NSCLC 337these mutations in the tumor specimens differed by at least
10-fold from the true germline SNPs in these same tumor
specimens that had allele frequencies in the range ofFigure 3 The Vfs for mutations identified in patient A (blue), patie
MET, (B) KRAS, (C) EGFR, and (D) ALK. For each plot, the amino
patient ID on the z-axis.32.37e99.98%, and (ii) the allele frequencies of these SNPs
are unknown in the dbSNP, and most of these SNPs were
generated from the Cancer Genome Project, while the true
germline SNPs in these tumor specimens have population
data reported in dbSNP.Discussion
Using ultradeep NGS, we were able to detect low fre-
quency mutations in key oncodriver genes associated with
treatment response to anti-EGFR therapy in patients with
CRC or NSCLC. The sensitivity of NGS, its extreme depth,
and its coverage allow such low frequency mutations to
become detectable, with more than 10,000  read depth
supporting the variant calls (22). The tumor specimen is a
heterogeneous, indistinguishable mixture of nonclonal so-
matic mutations and base call errors, the latter of which
have been introduced during DNA amplification and
sequencing, so ultradeep sequencing depth for each tar-
geted gene is necessary to accurately call variants with
frequencies that exceed the error level (17e20) with con-
fidence. Additionally, here we show the importance of
validating variant calls using a titration experiment as well
as an independent sequencing platform to reproduce low
frequency variant calls. Nevertheless, single cell PCR and
sequencing may be the ultimate way to make the unam-
biguous validation of low frequency mutations, but this
technology is still in its infancy and its utilization is beyond
the scope of this study.nt B (red), and patient C (green) tumor biopsy specimens in (A)
acid residues are on the x-axis, the Vfs on the y-axis, and the
Figure 4 FISH detection of the EML4-ALK fusion using a Spectrum Greenelabeled EML4 probe (green signal) and a Spectrum
Redelabeled ALK probe (red signal). (A) The EML4-ALK fusion gene is indicated with a white arrow in patient B; (B) both EML4 and
ALK gene copy numbers were increased in patient C.
338 L. Jiang et al.A limitation of this study is the lack of a germline control
for each CRC or NSCLC patient specimen, although at least
two independent sequencing runs (including new library
preparations) were conducted for 21 CRC patient speci-
mens, and for two of the three the NSCLC patients, two in-
dependent sequencing runs were conducted on two different
biological specimens (providing confidence in those variants
that were consistently identified). In addition, most of the
variants identified here are present in the Catalogue of So-
matic Mutations in Cancer (COSMIC) database and have
been associated with specific changes in tumors. De Grassi
et al. compared low frequency mutations in nonneoplastic
tissues from hereditary nonpolyposis colorectal cancer
(HNPCC) patients and healthy donors and found that low
frequency mutations were primarily associated with genomic
instability. More important, these mutations were present
only in the HNPCC patients and not in the healthy donors
(22), suggesting that the novel low frequency mutations
identified in this study may be associated with genomic
instability in the tumor specimens of these patients even if
such low frequency mutations are present in the germline.
It has been speculated that intratumor heterogeneity is at
least partially responsible for the discordance in mutation
status between different sites of a tumor, as well as varied
response to certain cancer treatments. The traditional
opinion that explains the manifestation and progression of
human cancers starts with a DNA mutation in a single cell,
followed by malignant cell clonal expansion and potential
additional genetic aberrations. This continuing acquisition of
genetic alterations can result in the emergence of tumor
subclones with varying phenotypic advantages, such as in-
vasion, proliferation, or the ability to colonize to different or-
gans (23). The presence of more than one clone of cancer
cells within a given tumor mass as well as the presence of
different genetic alterations in different metastatic tumors
from a single patient have been identified in several tumor
types (24e26).
If resistant clones are present at low frequency in the
primary tumor, a key question to address is whether they can
be detected at an early stage, thus influencing the choice of
primary therapy. Diaz et al. identified DNA mutations in the
KRAS gene in the circulation of 28 patients receivingmonotherapy with panitumumab and suggested that the
mutations were preexisting in the tumors before the initiation
of treatment (1). Our data indicate that approximately 13% of
pretreatment CRC tumors harbor low frequency mutations
(2.61e26.56%) in the GTPase nucleotideebiding site
domain of KRAS that are not detected by traditional Sanger
sequencing. In NSCLC patients, we also observed a low
frequency KRAS active mutation (G12R) and an EGFR ki-
nase domain mutation (G719A) in the same tumor specimen.
These findings, along with those from Diaz et al., suggest
that the resistance to EGFR inhibitor therapy in NSCLC pa-
tients could be the result of the expansion of cancer cells
harboring low frequency KRAS mutations, which effectively
inhibit EGFR-driven cancer clones.
Yang et al. reported that approximately 1.0% of NSCLC
patients (4/398) has concomitant EGFRmutations and EML4-
ALK fusions. Shaozhang et al. reported a concurrent KRAS
mutation and EML4-ALK fusion in 1 of 8 Asian NSCLC pa-
tients (12.5%) using Sanger sequencing and reverse tran-
scription PCR (RT-PCR), respectively (27). Here we identified
an EML4-ALK fusion presenting with multiple mutations in
ALK, EGFR, and MET in tumor specimens from a Chinese
NSCLC patient. Further, we found multiple low frequency
mutations in KRAS, EGFR, andMET that coexist with an ALK
copy number increase in another Chinese NSCLC patient.
However, most of the mutations in our study were present at
very low frequenciesdbelow those capable of being detected
by these previous studies that used traditional Sanger
sequencing. These results clearly indicate not only that mu-
tations can present in multiple oncogenes but also that one
gene from a patient can harbor several different mutations
and the frequency differences among these mutations indi-
cate that they likely arose from different clones of cells.
Current targeted cancer therapies usually lack durability
and demonstrate limited overall efficacy in patients. The
types of low frequency concurrent mutations in candidate
oncogenes presented here suggest necessary modifications
both to methods for detection of these variants and to gen-
eral treatment strategies. To date, Sanger sequencing has
been effectively used for detection of treatment-relevant so-
matic mutations. However, in a heterogeneous mixture of
cancerous and normal tissue, Sanger sequencing will likely
Oncogenic driver genes in CRC and NSCLC 339fail to detect low frequency mutations. Beyond the evidence
presented here, where Vfs less than approximately 26% are
not detected using Sanger sequencing, another study
demonstrated that Sanger sequencing failed to identify
EGFR mutations in primary lung tumor samples with
approximately 10% Vfs (28). ARMS-PCR assays, on the
other hand, are superior to Sanger sequencing in both
sensitivity and robustness on a large and diverse set of
clinical tumor specimens, although the assays are effective in
detecting known, well-characterized mutations. Since the
coexistence of several driver mutations within different, or
even the same, key oncogenes has such an impact on the
success of targeted cancer therapy, standard mutation-
detection strategies are not sufficient. More sensitive and
cost-effective sequencing methods are required to system-
atically assess the mutation status within cancer pathway
genes or at the whole genome level. Furthermore, because
patients often develop resistance to targeted therapy over
time that is due to the preexistence of low frequency muta-
tions in oncogenes, treatment strategies based on combi-
nation therapy might prove to be the most optimal treatment
approach for cancer patients. These hypotheses need to be
rigorously evaluated in future cancer trials.
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